<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40745">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575950</url>
  </required_header>
  <id_info>
    <org_study_id>EXP-1223</org_study_id>
    <nct_id>NCT02575950</nct_id>
  </id_info>
  <brief_title>Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne</brief_title>
  <official_title>Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 Applied in a Split-face (Left/Right) Topical Design in Adults With Moderate to Severe Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled,
      double-blinded, split-pace (left/right) design trial to evaluate the efficacy and
      tolerability of LEO 43204 in adults with moderate to severe acne.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total lesion count (inflammatory and non-inflammatory) in the treatment area for LEO 43204 gel and vehicle gel at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory lesion count in the treatment area for LEO 43204 gel and vehicle gel at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inflammatory lesion count in the treatment area for LEO 43204 gel and vehicle gel at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment of the treatment area at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite and component LSR score at all visits</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unacceptable LSR scores or unacceptable safety and tolerability events at all visits</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO43204 0,018%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO43204</intervention_name>
    <arm_group_label>LEO43204 0,018%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects should be diagnosed with acne vulgaris of the face

          -  Fitzpatrick skin types I-III (due to lack of safety data for the investigational
             product in darker skin types)

          -  Disease severity and total lesion count should be similar in both TAs

          -  Disease severity grade as moderate to severe according to the investigator's global
             assessment (grade 3-4)

          -  Age 18 to 35 years incl.

          -  Male or female

          -  Female Subjects must be of either non-childbearing potential or child-bearing
             potential with a confirmed negative pregnancy test

        Exclusion Criteria:

          -  Subjects with nodulocystic acne, acne conglobata, acne fulminans, secondary acne
             (e.g. chlor-acne, drug-induced acne)

          -  Subjects with previous history of keloid formation or post-inflammatory
             hyperpigmentation

          -  Systemic retinoids within 12 month or systemic antibiotics within 1 month before Day
             1

          -  Topical retinoids within 3 months before Day 1 or other topical treatments and/or
             medicated products and cosmetics that in the opinion of the investigator may
             influence the subjects acne vulgaris (including soaps containing antibacterial agents
             such as benzoyl peroxide, keratinolytic agents such as salicylic acid, skin
             fresheners/astringents or aftershave products) within 1 month before Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala Koudsi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Torrance Clinical Research Institute Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute Inc.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>February 10, 2017</lastchanged_date>
  <firstreceived_date>October 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
